At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 352 enrolled
Drug / intervention
Ticagrelor +1 moredrug
Likely dose
Ticagrelor 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Open-label, Parallel Group, Multi-center Study Using OCT to Comparing the Efficacy and Safety of Ticagrelor With Clopidogrel in the Prevention of Subclinical Thrombus in Patients After Drug-eluting Stent Implantation
Nanjing First Hospital, Nanjing Medical University·interventional·Posted May 16, 2014·Updated Mar 21, 2018
In Brief
A Phase 4 clinical trial evaluating Ticagrelor and Clopidogrel for Thrombosis. Completed, enrolled 352 participants across 1 site.
Detailed Summary
A number of 352 patients scheduled for elective percutaneous coronary intervention (PCI) with a native coronary stenosis suitable for DES implantation and OCT imaging are openly randomized 1:1 to either BRILINTA™ (ticagrelor) or Plavix® (clopidogrel bisulfate).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThrombosis
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMay 2014
First PostedMay 2014
Primary CompletionMar 2017
TodayJul 2026
First PostedMay 16, 2014
Enrollment StartMay 1, 2014
Primary CompletionMar 8, 2017
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 12.1 years ago
Interventions
Ticagrelordrug
Plain, round, yellow, filmcoated tablet, 90 mg
Clopidogreldrug
Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)